Zura Bio Limited

NASDAQ:ZURA

Biotechnology

Healthcare
$0.97 +1.93%

+$0.07 today

Market cap
$92.96M
Beta
0.03
P/E (TTM)
-5.5
EPS (TTM)
-$0.67
52W Low $1.00High $7.44

Volume 3.02M

Average 0.75M

ZURA Purchases of Investments

Cash used to buy marketable securities and other investments.

Zura Bio LimitedNASDAQ: ZURA

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments outflow grows to $0

Q1 FY2026 purchases of investments was $0, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was $0.

Context

  • Purchases of investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Purchases of Investments vs competitors

How ZURA compares with its peers on the latest reported figures

  • ZURA's LTM Mar 2026 purchases of investments of $0 is the 9th largest of the 11 companies compared; the peer median is $87.35M.
ZURA Competitors Peer median
Purchases of Investments for ZURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$345.19M +129.9%+6.9%498.7%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$274.16M +157.1%+103.4%385.6%
IMRXImmuneering CorporationLTM Mar 2026$160.59M —+20.9%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$147.06M -47.7%-31.6%521.0%
SGMTSagimet Biosciences Inc.LTM Mar 2026$98.04M -52.5%+37.1%—
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$76.65M -17.7%-27.0%—
PYXSPyxis Oncology, Inc.LTM Mar 2026$66.65M -43.8%—480.9%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$4.95M -96.0%——
ZURAZura Bio LimitedLTM Mar 2026$0 ———
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 ——0.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$0 +100.0%—0.0%
Peer median (excluding ZURA) $87.35M-30.8%+13.9%433.3%

Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income8.42M(27.33M)(60.56M)(52.4M)(68.65M)
Depreciation & Amortization0009K49K
Deferred Income Tax00000
Stock-Based Compensation0334K9.66M16.8M12.33M
Change in Working Capital(235.6K)3.54M5.12M2.31M(3.63M)
Accounts Receivables2.87K0000
Inventory00000
Accounts Payables0288.29K04.21M(2.16M)
Other Working Capital(238.47K)3.25M5.12M(1.91M)(1.47M)
Other Non-Cash Items(9.28M)22.26M30.74M5.21M(4.91M)
Operating Cash Flow(1.1M)(1.2M)(15.05M)(28.08M)(64.82M)
Capital Expenditures(4)(12M)(8M)(75K)(113K)
Acquisitions (Net)00000
Purchases of Investments(139.38M)0000
Sales of Investments00000
Other Investing Activities000(5M)0
Investing Cash Flow(139.38M)(12M)(8M)(5.08M)(113K)
Debt Repayment(117.38K)7.6M(10M)00
Common Stock Issued140.82M0116.41M60.76M5.2M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities505K(2.83M)14.89M49.09M(7.37M)
Financing Cash Flow141.21M14.77M121.29M109.84M(2.16M)
Effect of Forex Changes00000
Net Change in Cash729.22K1.57M98.24M76.69M(67.09M)
Free Cash Flow(1.1M)(13.2M)(23.05M)(28.15M)(64.93M)

Zura Bio Limited

NASDAQ:ZURA

Intrinsic Alpha fair value

Locked

Current Price

$0.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.